CagriSema Tracker App
Track the Next-Gen Combination Treatment
Prepare to track CagriSema - Novo Nordisk's combination of cagrilintide (amylin analog) and semaglutide (GLP-1). Phase 3 trials show up to 24% weight loss, rivaling even tirzepatide's results. Be ready when it launches.
What is CagriSema?
CagriSema combines two mechanisms: cagrilintide (a long-acting amylin analog) + semaglutide (GLP-1 agonist). By targeting both the amylin and GLP-1 pathways, it provides complementary appetite suppression and metabolic benefits.
In Phase 2 trials, CagriSema produced up to 24% weight loss - comparable to tirzepatide and retatrutide. Novo Nordisk expects FDA approval in 2025-2026. Shotlee will be ready to track it immediately.
FAQ
How is CagriSema administered?
CagriSema will likely be a once-weekly injection combining both active ingredients. Shotlee will support complete tracking when approved.
Can I track Wegovy now while waiting?
Absolutely! CagriSema contains semaglutide - the same ingredient in Wegovy. Start tracking your semaglutide journey with Shotlee now.